Cannara Biotech Inc. Experiences Q1 2023 Monetary Outcomes

Firm recorded $10.3 million in quarterly income; a 57% enhance in comparison with Q1 2022 Delivered its seventh consecutive quarter of constructive Adjusted EBITDA of $1.7M and reported constructive internet revenue for a second consecutive quarter Continued to extend rising capability to satisfy buyer demand by activating new rising zone in its increasing Valleyfield Facility […]